Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Humate-P®
[Antihemophilic Factor/von Willebrand Factor Complex (Human)]
Lyophilized Powder for Reconstitution for Intravenous Use Only
Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human), is a purified, sterile, lyophilized concentrate of Factor VIII (FVIII) and von Willebrand Factor (VWF) (Human) for intravenous administration in the treatment of patients with classical hemophilia (hemophilia A) and VWD [see CLINICAL PHARMACOLOGY].
Humate-P is purified from the cold insoluble fraction of pooled human plasma. The pooled human plasma used to produce Humate-P is collected from licensed facilities in the United States (US). All source plasma used in the manufacture of Humate-P is tested by FDA-licensed Nucleic Acid Tests (NAT) for hepatitis C virus (HCV), human immunodeficiency virus-1 (HIV-1), hepatitis A virus (HAV), and hepatitis B virus (HBV) and found to be nonreactive (negative).
Each vial of Humate-P contains the labeled amount of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and FVIII activity expressed in International Units (IU) [see Dosage Forms And Strengths], as defined by the current international standard established by the World Health Organization. One International Unit (IU) of VWF:RCo or FVIII is approximately equal to the amount of VWF:RCo or FVIII in 1.0 mL of fresh-pooled human plasma. The average ratio of VWF:RCo to FVIII is 2.4:1.Fibrinogen content in Humate-P is less than or equal to 0.2 mg/mL. Humate-P contains anti-A and anti-B blood group isoagglutinins [see WARNINGS AND PRECAUTIONS].
When reconstituted with the volume of Sterile Water for Injection, USP provided, each mL of Humate-P contains 72 to 224 International Units (IU) VWF:RCo activity,* 40 to 80 International Units (IU) FVIII activity, 15 to 33 mg of glycine, 3.5 to 9.3 mg of sodium citrate, 2 to 5.3 mg of sodium chloride, 8 to 16 mg of Albumin (Human), 2 to 4 mg of other proteins, and 10 to 20 mg of total proteins. Humate-P contains no preservative.
The manufacturing procedure for Humate-P includes multiple processing steps that reduce the risk of virus transmission. The virus inactivation/removal capacity consists of four steps:
The total cumulative virus reductions range from 6.0 to ≥11.7 log10 as shown in Table 7.
Table 7: Cumulative Virus Reduction Factors for
Humate-P
| Manufacturing Step | Virus Reduction Factor (log10) | ||||||
| Enveloped Viruses | Non-Enveloped Viruses | ||||||
| HIV-1 | BVDV | PRV | WNV | HAV | CPV | B19V | |
| Cryoprecipitation | ND | ND | 1.6 | ND | ND | 1.9 | ND |
| Al(OH)3 Adsorption/ Glycine Precipitation/ NaCl Precipitation | 3.8 | 2.8 | 3.9 | ND | 2.3 | 3.0 | ND |
| Heat Treatment* | ≥6.4 | ≥8.9 | 4.7 | ≥7.8 | 4.2 | 1.1 | ≥3.9† |
| Lyophilization | ND | ND | ND | ND | 1.3 | ND | ND |
| Cumulative Virus Reduction [log10] | ≥10.2 | ≥11.7 | 10.2 | NA | 7.8 | 6.0 | NA |
| HIV-1, human immunodeficiency virus type 1, model for
HIV-1 and HIV-2 BVDV, bovine viral diarrhea virus, model for HCV PRV, pseudorabies virus, model for large enveloped DNA viruses WNV, West Nile virus HAV, hepatitis A virus CPV, canine parvovirus, model for B19V B19V, human parvovirus B19 ND, not determined NA, not applicable * At 60°C for 10 hours in aqueous solution. † The virus evaluation studies for B19V employed a novel experimental infectivity assay using a clone of the cell line UT7 that contains erythropoietic progenitor cells; (residual) virus titer was determined using an immunofluorescence-based detection method. |
|||||||
REFERENCES
*This correlates to a VWF:RCo to FVIII activity average ratio of 2.4:1, which is used to calculate the nominal values of VWF:RCo activity and is the average VWF:RCo activity.
Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human), is indicated for treatment and prevention of bleeding in adults with hemophilia A (classical hemophilia).
Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for:
Controlled clinical trials to evaluate the safety and efficacy of prophylactic dosing with Humate-P to prevent spontaneous bleeding have not been conducted in VWD subjects [see Clinical Studies].
One International Unit (IU) of Factor VIII (FVIII) activity per kg body weight will increase the circulating FVIII level by approximately 2.0 International Units (IU)/dL. Dosage must be individualized based on the patient’s weight, type and severity of hemorrhage, FVIII level, and presence of inhibitors. Judge the adequacy of treatment by clinical effects and, in all cases, adjust doses as needed based on clinical judgment and on frequent monitoring of the patient’s FVIII level. Table 1 provides dosing recommendations for the treatment of hemophilia A in adults.
Table 1: Dosing Recommendations for the Treatment of
Hemophilia A in Adults1
| Hemorrhagic Event | Dosage (IU FVIII:C/kg Body Weight) |
Minor hemorrhage:
|
Loading dose 15 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 30% of normal; one infusion may be sufficient. If needed, half of the loading dose may be given once or twice daily for 1-2 days. |
Moderate hemorrhage:
|
Loading dose 25 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 50% of normal, followed by 15 IU FVIII:C/kg every 8-12 hours for the first 1-2 days to maintain the FVIII:C plasma level at 30% of normal. Continue the same dose once or twice daily for up to 7 days or until adequate wound healing is achieved. |
Life-threatening hemorrhage:
|
Initially 40-50 IU FVIII:C/kg, followed by 2025 IU FVIII:C/kg every 8 hours to maintain the FVIII:C plasma level at 80-100% of normal for 7 days. Continue the same dose once or twice daily for another 7 days to maintain the FVIII:C level at 30-50% of normal. |
| IU = International Units. | |
Administer 40 to 80 International Units (IU) VWF:RCo (corresponding to 17 to 33 International Units (IU) FVIII in Humate-P) per kg body weight every 8 to 12 hours. Adjust the dosage based on the extent and location of bleeding. Administer repeat doses as long as needed based on monitoring of appropriate clinical and laboratory measures [see WARNINGS AND PRECAUTIONS]. Expected levels of VWF:RCo are based on an expected in vivo recovery (IVR) of 2.0 International Units (IU)/dL rise per International Unit (IU)/kg VWF:RCo administered. The administration of 1 IU of FVIII per kg body weight can be expected to lead to a rise in circulating VWF:RCo of approximately 5 International Units (IU)/dL. Table 2 provides dosing recommendations for adult and pediatric patients [see Use In Specific Populations].2
Table 2: VWF:RCo Dosing Recommendations for the
Treatment of Bleeding Episodes by VWD Type
| VWD Type | Severity of Hemorrhage | Dosage (IU* VWF:RCo/kg Body Weight) |
| Type 1 VWD - Mild (baseline VWF:RCo activity typically >30%) | Minor (e.g., epistaxis, oral bleeding, menorrhagia) | Typically treatable with desmopressin. |
| Minor (when desmopressin is known or suspected to be inadequate) Major† (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, traumatic hemorrhage) |
Loading dose 40-60 lU/kg. Then 40-50 lU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-50 lU/kg daily for up to 7 days. | |
| Type 1 VWD -Moderate or severe (baseline VWF:RCo typically <30%) | Minor (e.g., epistaxis, oral bleeding, menorrhagia) | 40-50 lU/kg (1 or 2 doses). |
| Major (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage) | Loading dose 50-75 lU/kg. Then 40-60 lU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-60 lU/kg daily for up to 7 days. | |
| Type 2 VWD (all variants) and Type 3 VWD | Minor (clinical indications above) | 40-50 lU/kg (1 or 2 doses). |
| Major (clinical indications above) | Loading dose 60-80 lU/kg. Then 40-60 lU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-60 lU/kg daily for up to 7 days. | |
| * IU = International Units. † For major bleeds in all types of VWD where repeated dosing is required, monitor and maintain the patient’s FVIII level according to the guidelines for hemophilia A therapy. |
||
The following information provides guidelines for calculating loading and maintenance doses of Humate-P for patients undergoing surgery. However in the case of emergency surgery, administer a loading dose of 50 to 60 International Units (IU) VWF:RCo/kg body weight and, subsequently, closely monitor the patient’s trough coagulation factor levels. Measure incremental IVR and assess plasma VWF:RCo and FVIII:C levels in all patients prior to surgery when possible.
To determine IVR:
Use the following formula to calculate IVR:
IVR = (Plasma VWF:RCotime+30 min – Plasma VWF:RCobaseline International Units (IU)/dL)/ Calculated dose (International Units (IU)/kg)
For example, assuming a baseline VWF:RCo of 30 International Units (IU)/dL at “time 0”, a calculated dose of 60 International Units (IU)/kg, and a VWF:RCo of 120 International Units (IU)/dL at “time+30 minutes”, the IVR would be 1.5 International Units (IU)/dL per International Units (IU)/kg of VWF:RCo administered.
Table 3 provides guidelines for calculating the loading dose for adult and pediatric patients based on the target peak plasma VWF:RCo level, the baseline VWF:RCo level, body weight in kilograms, and IVR. When individual recovery values are not available, a standardized loading dose can be used based on an assumed VWF:RCo IVR of 2.0 International Units (IU)/dL per International Unit (IU)/kg of VWF:RCo administered.
Table 3: VWF:RCo and FVIII:C Loading Dose Calculations
for the Prevention of Excessive Bleeding During and After Surgery for All Types
of VWD
| Type of Surgery | VWF:RCo Target Peak Plasma Level | FVIII:C Target Peak Plasma Level | Calculation of Loading Dose (to be administered 1 to 2 hours before surgery) |
| Major | 100 IU/dL | 80-100 IU/dL | Δ* VWF:RCo x BW (kg)/IVR† = IU VWF:RCo required |
| Minor/Oral* | 50-60 IU/dL | 40-50 IU/ dL | Δ * VWF:RCo x BW (kg) IVR/ = IU VWF:RCo required |
| Emergency | 100 IU/dL | 80-100 IU/dL | Administer a dose of 50-60 IU VWF:RCo/ kg body weight. |
| IU = International Units. BW = body weight. * Δ = Target peak plasma VWF:RCo level – baseline plasma VWF:RCo level. † IVR = in vivo recovery as measured in the patient. ‡ Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients. |
|||
For example, the loading dose of Humate-P required assuming a target VWF:RCo level of 100 International Units (IU)/dL, a baseline VWF:RCo level of 20 International Units (IU)/dL, an IVR of 2.0 International Units (IU)/dL per International Units (IU)/kg, and a body weight of 70 kg would be 2,800 International Units (IU) VWF:RCo, calculated as follows:
(100 IU/dL – 20 IU/dL) x 70 kg/2.0 (IU/dL)/(IU/kg) = 2,800 IU VWF:RCo required
IU = International Units.
Attaining a target peak FVIII:C plasma level of 80 to 100 International Units (IU) FVIII:C/ dL for major surgery and 40 to 50 International Units (IU) FVIII:C/dL for minor surgery or oral surgery might require additional dosing with Humate-P. Because the ratio of VWF:RCo to FVIII:C activity in Humate-P is 2.4:1, any additional dosing will increase VWF:RCo proportionally more than FVIII:C. Assuming an incremental IVR of 2.0 International Units (IU) VWF:RCo/dL per International Units (IU)/kg infused, additional dosing to increase FVIII:C in plasma will also increase plasma VWF:RCo by approximately 5 International Units (IU)/dL for each International Unit (IU)/kg of FVIII administered.
The initial maintenance dose of Humate-P for the prevention of excessive bleeding during and after surgery should be half of the loading dose, irrespective of additional dosing required to meet FVIII:C targets. Subsequent maintenance doses should be based on the patient’s VWF:RCo and FVIII levels. Table 4 provides recommendations for target trough plasma levels (based on type of surgery and number of days following surgery) and minimum duration of treatment for subsequent maintenance doses. These recommendations apply to both adult and pediatric patients.
Table 4: VWF:RCo and FVIII:C Target Trough Plasma
Level and Minimum Duration of Treatment Recommendations for Subsequent
Maintenance Doses for the Prevention of Excessive Bleeding During and After
Surgery
| Type of Surgery | VWF:RCo Target Trough Plasma Level* | FVIII:C Target Trough Plasma Level* | Minimum Duration of Treatment | ||
| Up to 3 days following surgery | After Day 3 | Up to 3 days following surgery | After Day 3 | ||
| Major | >50 IU/dL | >30 IU/dL | >50 IU/dL | >30 IU/dL | 72 hours |
| Minor | ≥30 IU/dL | - | - | >30 IU/dL | 48 hours |
| Oral† | ≥30 IU/dL | - | - | >30 IU/dL | 8-12 hours‡ |
| IU = International Units. * Trough levels for either coagulation factor should not exceed 100 IU/dL. † Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients. ‡ Administer at least one maintenance dose following oral surgery based on individual pharmacokinetic values. Subsequent therapy with an antifibrinolytic agent is usually administered until adequate healing is achieved. |
|||||
Based on individual pharmacokinetic-derived half-lives, the frequency of maintenance doses is generally every 8 or 12 hours; patients with shorter half-lives may require dosing every 6 hours. In the absence of pharmacokinetic data, it is recommended that Humate-P be administered initially every 8 hours with further adjustments determined by monitoring trough coagulation factor levels. When hemostatic levels are judged insufficient or trough levels are outside the recommended range, consider modifying the administration interval and/or the dose.
It is advisable to monitor trough VWF:RCo and FVIII:C levels at least once a day in order to adjust Humate-P dosing as needed to avoid excessive accumulation of coagulation factors. The duration of treatment generally depends on the type of surgery performed, but must be assessed for individual patients based on their hemostatic response [see Clinical Studies].
Humate-P is for intravenous use only.
1. Ensure that the Humate-P vial and diluent vial are at room temperature.
2. Place the Humate-P vial, diluent vial and Mix2Vial transfer set on a flat surface.
3. Remove the Humate-P and diluent vial flip caps. Wipe the stoppers with an alcohol swab. Allow the stoppers to dry prior to opening the Mix2Vial transfer set package.
4. Open the Mix2Vial transfer set package by peeling away the lid (Figure 1). Leave the Mix2Vial transfer set in the clear package.
Figure 1
 |
5. Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plastic spike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial (Figure 2).
Figure 2
 |
6. Carefully remove the clear package from the Mix2Vial transfer set. Make sure that you pull up only the clear package and not the Mix2Vial transfer set (Figure 3).
Figure 3
 |
7. With the Humate-P vial placed firmly on a flat surface, invert the diluents vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the Humate-P vial (Figure 4). The diluent will automatically transfer into the Humate-P vial.
Figure 4
 |
8. With the diluent and Humate-P vial still attached to the Mix2Vial transfer set, gently swirl the Humate-P vial to ensure the Humate-P is fully dissolved (Figure 5). Do not shake the vial.
Figure 5
 |
9. With one hand grasp the Humate-P side of the Mix2Vial transfer set and with the other hand grasp the blue diluent-side of the Mix2Vial transfer set, and unscrew the set into two pieces (Figure 6).
Figure 6
 |
10. Draw air into an empty, sterile syringe. While the Humate-P vial is upright, screw the syringe to the Mix2Vial transfer set. Inject air into the Humate-P vial. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly (Figure 7).
Figure 7
 |
11. Now that the concentrate has been transferred into the syringe, firmly grasp the barrel of the syringe (keeping the syringe plunger facing down) and unscrew the syringe from the Mix2Vial transfer set (Figure 8). Attach the syringe to a suitable intravenous administration set.
Figure 8
 |
12. If patient requires more than one vial, pool the contents of multiple vials into one syringe. Use a separate unused Mix2Vial for each product vial.
Humate-P is available as a sterile, lyophilized powder for intravenous administration following reconstitution. Each vial of Humate-P contains the labeled amount of VWF:RCo and FVIII activity expressed in International Units (IU). The average ratio of VWF:RCo to FVIII is 2.4:1.
Approximate potencies are shown below; check each carton/vial for the actual potency prior to reconstitution:
| VWF:RCo/vial | FVIII/vial | Diluent |
| 600 IU | 250 IU | 5 mL |
| 1200 IU | 500 IU | 10 mL |
| 2400 IU | 1000 IU | 15 mL |
| IU = International Units. | ||
Each product presentation includes a package insert and the following components:
| Presentation | Carton NDC Number | Components |
| 600 IU VWF:RCo and 250 IU FVIII | 63833-615-02 |
|
| 1200 IU VWF:RCo and 500 IU FVIII | 63833-616-02 |
|
| 2400 IU VWF:RCo and 1000 IU FVIII | 63833-617-02 |
|
REFERENCES
1. Levine PH, Brettler DB. Clinical aspects and therapy for hemophilia A. In: Hoffman R, Benz JB, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: Basic Principles and Practice. New York: Churchill Livingstone Inc.; 1991:1296-1297.
2. Scott JP, Montgomery RT. Therapy of von Willebrand disease. Semin Thromb Hemost. 1993;19:37-47.
Manufactured by: CSL Behring GmbH 35041 Marburg, Germany, US License No. 1765. Distributed by: CSL Behring LLC, Kankakee, IL 60901 USA. Revised: Sep 2017
The most serious adverse reaction observed in patients receiving Humate-P is anaphylaxis. Thromboembolic events have also been observed in patients receiving Humate-P for the treatment of VWD [see WARNINGS AND PRECAUTIONS]. Reports of thromboembolic events in VWD patients with other thrombotic risk factors receiving coagulation factor replacement therapy have been obtained from spontaneous reports, published literature, and a European clinical study. In some cases, inhibitors to coagulation factors may occur. However, no inhibitor formation was observed in any of the clinical studies.
In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions (including urticaria, chest tightness, rash, pruritus, and edema). For patients undergoing surgery, the most common adverse reactions are postoperative wound and injection-site bleeding, and epistaxis.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.
Allergic symptoms, including allergic reaction, urticaria, chest tightness, rash, pruritus, and edema, were reported in 6 of 97 (6%) subjects in a Canadian retrospective study [see Clinical Studies]. Four of 97 (4%) subjects experienced seven adverse events that were considered to have a possible or probable relationship to Humate-P. These included chills, phlebitis, vasodilation, paresthesia, pruritus, rash, and urticaria. All were mild in intensity with the exception of a moderate case of pruritus.
In a prospective, open-label safety and efficacy study of Humate-P in VWD subjects with serious life- or limb-threatening bleeding or undergoing emergency surgery, seven of 71 (10%) subjects experienced nine adverse reactions. These were one occurrence each of mild vasodilation and mild pruritis; two occurrences of mild paresthesia; and one occurrence each of moderate peripheral edema and extremity pain and severe pseudothrombocytopenia (platelet clumping with a false low reading). Humate-P was discontinued in the subject who experienced the peripheral edema and extremity pain.
Among the 63 VWD subjects who received Humate-P for prevention of excessive bleeding during and after surgery, including one subject who underwent colonoscopy without the planned polypectomy, the most common adverse events were postoperative hemorrhage (35 events in 19 subjects with five subjects experiencing bleeding at up to three different sites), postoperative nausea (15 subjects), and postoperative pain (11 subjects). Table 5 presents the postoperative hemorrhagic adverse events.
Table 5: Hemorrhagic Adverse Events in 63 Surgical
Subjects
| Adverse Event | Surgical Procedure Category | Number of Subjects/ Events | Onset* (Number of Events) | Severity (Number of Events) | |||
| On | Post | Mild | Mod | Severe | |||
| Wound/injection site bleeding | Major | 8/11 | 7 | 4 | 9 | - | 2 |
| Minor | 2/2 | 2 | - | 1 | 1 | - | |
| Oral | 2/6 | - | 6 | 3 | 3 | - | |
| Epistaxis | Major | 4/4 | 2 | 2 | 3 | 1 | - |
| Minor | 1/1 | 1 | - | 1 | - | - | |
| Cerebral hemorrhage/ subdural hematoma | Major | ½ | 2† | - | - | 2 | - |
| Gastrointestinal bleeding | Major | 1/3 | 3‡ | - | - | 2 | 1 |
| Menorrhagia | Major | 1/1 | 1§ | - | - | 1 | - |
| Groin bleed | Oral | 1/1 | - | 1 | 1 | - | - |
| Ear bleed | Major | 1/1 | 1 | - | 1 | - | - |
| Hemoptysis | Major | 1/1 | 1 | - | 1 | - | - |
| Hematuria | Major | 1/1 | 1 | - | 1 | - | - |
| Shoulder bleed | Major | 1/1 | 1 | - | 1 | - | - |
| * On = on-therapy; onset while receiving Humate-P or
within 1 day of completing Humate-P administration. Post = post-therapy; onset
at least one day after completing Humate-P administration. † Reported as serious adverse events following intracranial surgery. ‡ Two of these events were reported as serious adverse events following gastrojejunal bypass. § Reported as a serious adverse event requiring hysterectomy following hysteroscopy and dilation and curettage. |
|||||||
Table 6 lists the non-hemorrhagic adverse events reported in at least two subjects, regardless of causality, and the adverse events that were possibly related to Humate-P. Pulmonary embolus considered possibly related to Humate-P occurred in one elderly subject who underwent bilateral knee replacement.
Table 6: Non-Hemorrhagic and Possibly Related Adverse
Events in 63 Surgical Subjects
| Body System | Adverse Event (AE) | Number of Subjects With an AE Possibly Related to Humate-P | Number of Subjects With an AE Regardless of Causality* |
| Body as a whole | Pain | - | 11 |
| Fever | - | 4 | |
| Abdominal pain | - | 3 | |
| Infection | - | 3 | |
| Surgery | - | 3 | |
| Back pain | - | 2 | |
| Facial edema | - | 2 | |
| Cardiovascular | Chest pain | - | 3 |
| Pulmonary embolust | 1 | 1 | |
| Thrombophlebitis† | 1 | 1 | |
| Digestive | Nausea | 1 | 15 |
| Constipation | - | 7 | |
| Vomiting | 1 | 3 | |
| Sore throat | - | 2 | |
| Hemic and lymphatic system | Anemia/decreased hemoglobin | - | 2 |
| Metabolic/ nutritional | Increased SGPT | 1 | 1 |
| Nervous | Dizziness | 1 | 5 |
| Headache | 1 | 4 | |
| Increased sweating | - | 3 | |
| Insomnia | - | 2 | |
| Skin and appendages | Pruritus | - | 3 |
| Rash | 1 | 1 | |
| Urogenital | Urinary retention | - | 4 |
| Urinary tract infection | - | 2 | |
| * Events occurring in two or more subjects. † Events occurring in separate subjects. |
|||
Eight subjects experienced 10 postoperative serious adverse events: one with subdural hematoma and intracerebral bleeding following intracranial surgery related to an underlying cerebrovascular abnormality; one with two occurrences of gastrointestinal bleeding following gastrojejunal bypass; and one each with sepsis, facial edema, infection, menorrhagia requiring hysterectomy following hysteroscopy and dilation and curettage, pyelonephritis, and pulmonary embolus.
The following adverse reactions have been identified during postapproval use of Humate-P. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Humate-P exposure.
Adverse reactions reported in patients receiving Humate-P for treatment of VWD or hemophilia A are allergic-anaphylactic reactions (including urticaria, chest tightness, rash, pruritus, edema, and shock), development of inhibitors to FVIII, and hemolysis. Additional adverse reactions reported for VWD are thromboembolic complications, chills and fever, and hypervolemia.
None reported.
Included as part of the PRECAUTIONS section.
Thromboembolic events have been reported in VWD patients receiving Antihemophilic Factor/ von Willebrand Factor Complex replacement therapy, especially in the setting of known risk factors for thrombosis.3,4 Early reports indicate a higher incidence may occur in females. Endogenous high levels of FVIII have also been associated with thrombosis, but no causal relationship has been established. Exercise caution and consider antithrombotic measures in all at-risk VWD patients who are receiving coagulation factor replacement therapy.
Humate-P contains blood group isoagglutinins (anti-A and anti-B). When doses are very large or need to be repeated frequently (for example, when inhibitors are present or when pre- and post-surgical care is involved), monitor patients of blood groups A, B, and AB for signs of intravascular hemolysis and decreasing hematocrit values and treat appropriately.
Monitor the VWF:RCo and FVIII levels of VWD patients receiving Humate-P using standard coagulation tests, especially in cases of surgery. It is advisable to monitor trough VWF:RCo and FVIII:C levels at least once a day in order to adjust the dosage of Humate-P as needed to avoid excessive accumulation of coagulation factors [see DOSAGE AND ADMINISTRATION].
Because Humate-P is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt- Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent [see DESCRIPTION and PATIENT INFORMATION]. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing [see DESCRIPTION].
Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Thus the risk of transmission of infectious agents cannot be eliminated completely. Report all infections thought by a physician possibly to have been transmitted by this product to CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800- FDA-1088 or www.fda.gov/medwatch.
Some viruses, such as Parvovirus B19 virus (B19V) or hepatitis A (HAV), are particularly difficult to remove or inactivate. B19V may most seriously affect pregnant women and immune-compromised individuals.
Although the overwhelming number of B19V and HAV cases are community acquired, reports of these infections have been associated with the use of some plasma-derived products. Therefore, physicians should be alert to the potential symptoms of B19V and HAV infections [see PATIENT INFORMATION].
Symptoms of B19V may include low-grade fever, rash, arthralgia, and transient symmetric, nondestructive arthritis. Diagnosis is often established by measuring B19V-specific IgM and IgG antibodies. Symptoms of HAV include low-grade fever, anorexia, nausea, vomiting, fatigue, and jaundice. A diagnosis may be established by measuring specific IgM antibodies.
Physicians should strongly consider administration of hepatitis A and hepatitis B vaccines to individuals receiving plasma derivatives. Potential risks and benefits of vaccination should be weighed by the physician and discussed with the patient.
Animal reproduction studies have not been conducted with Humate-P. It is also not known whether Humate-P can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Humate-P should be given to a pregnant woman only if clearly needed.
It is not known whether Humate-P can cause harm to the mother or the fetus when administered during labor and delivery. Humate-P should be given during labor and delivery only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Humate-P is administered to a nursing woman.
Adequate and well-controlled studies with long-term evaluation of joint damage have not been done in pediatric subjects. Joint damage may result from suboptimal treatment of hemarthroses.
The safety and effectiveness of Humate-P for the treatment of VWD was demonstrated in 26 pediatric subjects, including infants, children, and adolescents, but have not been evaluated in neonates. The safety of Humate-P for the prevention of excessive bleeding during and after surgery was demonstrated in eight pediatric subjects (ages 3 to 15) with VWD. Of the 34 pediatric subjects studied for either treatment of bleeding episodes in VWD or prevention of excessive bleeding during and after surgery, four were infants (1 month to under 2 years of age), 23 were children (2 through 12 years), and seven were adolescents (13 through 15 years).
As in adults, pediatric patients should be dosed based on body weight (kg) [see DOSAGE AND ADMINISTRATION].
Clinical studies of Humate-P did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. As for all patients, dosing for geriatric patients should be appropriate to their overall situation.
REFERENCES
3. Mannucci, PM. Venous Thromboembolism in Von Willebrand Disease. Thromb Haemostas. 2002;88:378-379.
4. Markis M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemostas. 2002;88:387-388.
No Information provided
Humate-P is contraindicated in individuals who have had an anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor preparations.
The active components of Humate-P consist of two different noncovalently bound proteins (FVIII and VWF). FVIII is an essential cofactor in activation of factor X, leading ultimately to the formation of thrombin and, subsequently, fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; activated platelets interact with clotting proteins to form a clot. VWF also serves as a stabilizing carrier protein for the procoagulant protein FVIII.5,6 The activity of VWF is measured as VWF:RCo.
After infusion of Humate-P, a rapid increase of plasma FVIII:C is followed by a rapid decrease in activity and, subsequently, a slower rate of decrease in activity. Studies with Humate-P in subjects with hemophilia A have demonstrated a mean half-life of 12.2 (range: 8.4 to 17.4) hours.
The pharmacokinetics of Humate-P were studied in 41 subjects in a US study and in 28 subjects in a European study [see Clinical Studies]. In both studies, subjects were evaluated in the nonbleeding state prior to a surgical procedure. Table 8 summarizes the pharmacokinetics of Humate-P based on these studies. Wide inter-subject variability was observed in pharmacokinetic values obtained from these studies.
Table 8: Pharmacokinetics of Humate-P in Two Studies
of Subjects in the Non- Bleeding State Prior to Surgery
| US Study | European Study | |
| Number of subjects | 41 | 28 |
| Type 1 VWD | 16 | 10 |
| Type 2A VWD | 2 | 10 |
| Type 2B VWD | 4 | -- |
| Type 2M VWD | 6 | 1 |
| Type 3 VWD | 13 | 7 |
| Dosage of Humate-P | 60 IU VWF:RCo/kg BW | 80 IU VWF:RCo/kg BW |
| Median terminal half-life of VWF:RCo (range) | 11 hours* (3.5-33.6) | 10 hours† (2.8-28.3) |
| Median clearance (range) | 3.1 mL/hr/kg (1-16.6) | 4.8 mL/hr/kg (2.1-53) |
| Volume of distribution at steady state (range) | 53 mL/kg (29-141) | 59 mL/kg (32-290) |
| Median IVR for VWF:RCo activity (range) | 2.4 IU/dL per IU/kg (1.1-4.2) | 1.9 IU/dL per IU/kg (0.6-4.5) |
| IU = International Units. BW = body weight. * Excluding 5 subjects with a half-life exceeding the blood sampling time of 24 or 48 hours. † Excluding 1 subject with a half-life exceeding the blood sampling time of 48 hours. |
||
Humate-P has been demonstrated in several studies to contain the high molecular weight multimers of VWF. The presence of a multimeric composition of VWF in Humate-P is similar to that found in normal plasma and this component is considered to be important for correcting the coagulation defect in patients with VWD.7,8
The multimeric patterns of Humate-P in the US study were measured in 13 subjects with type 3 VWD; 11 had absent or barely detectable multimers at baseline. Of those 11 subjects, all had some high molecular weight multimers present 24 hours after infusion of Humate-P. In the European study, infusion of Humate-P corrected the defect of the multimer pattern in subjects with types 2A and 3 VWD. High molecular weight multimers were detectable until at least 8 hours after infusion.
Based on the small sample size evaluation, it appears that age, sex, and type of VWD have no impact on the pharmacokinetics of VWF:RCo.
Controlled clinical studies to evaluate the safety and efficacy of prophylactic dosing with Humate-P to prevent spontaneous bleeding have not been conducted in VWD subjects. Adequate data are not presently available on which to evaluate or to base dosing recommendations in this setting.
Clinical efficacy of Humate-P in the control of bleeding in subjects with VWD was determined by a retrospective review of clinical safety and efficacy data obtained from 97 Canadian VWD subjects who received product under an Emergency Drug Release Program. The dosage schedule and duration of therapy were determined by the medical practitioner.
There were 514 requests for product use for surgery, bleeding, or prophylaxis in the 97 subjects. Of these, Humate-P was not used in 151 cases, and follow-up safety and/or efficacy information was available for 303 (83%) of the remaining 363 requests. In many cases, Humate-P from a single request was used for several treatment courses in one subject. Therefore, there are more reported treatment courses than requests.
Humate-P was administered to 97 subjects in 530 treatment courses: 73 for surgery, 344 for treatment of bleeding, and 20 for prophylaxis of bleeding. The majority of the 93 “other” uses involved dental procedures, diagnostic procedures, prophylaxis prior to a procedure, or test doses.
Table 9 summarizes the dosing information (all subjects) for bleeding episodes.
Table 9: Dosing Information for Bleeding Episodes in VWD
| Type/Location of Bleeding Episode | ||||||
| Digestive System | Nose + Mouth +Pharynx | Integument System | Female System | Musculo - skeletal | ||
| No. of Subjects | 14 | 29 | 11 | 4 | 22 | |
| Loading Dose | Mean Dose (SD)* | 62.1 (31.1) | 66.9 (24.3) | 73.4 (37.7) | 88.5 (28.3) | 50.2 (24.9) |
| No. of Infusions† | 37 | 127 | 22 | 7 | 107 | |
| Maintenance Dose | Mean Dose (SD)* | 61.5 (38.0) | 67.5 (22.4) | 56.5 (63.3) | 74.5 (17.7) | 63.8 (28.8) |
| No. of Infusions† | 250 | 55 | 4 | 15 | 121 | |
| No. of Treatment Days per | Mean (SD) | 4.6 (3.6) | 1.4 (1.2) | 1.1 (0.4) | 2.8 (2.9) | 2.0 (1.9) |
| Bleeding Episode | No. of Events | 49 | 130 | 22 | 9 | 108 |
| No. of Infusions by Treatment Day | ||||||
| No. of Subjects | 14 | 29 | 11 | 4 | 22 | |
| Mean (SD) | 1.2 (0.4) | 1.1 (0.2) | 1.0 (0.2) | 1.0 (0.0) | 1.0 (0.1) | |
| Day 1‡ | No. of Events | 49 | 130 | 22 | 9 | 108 |
| No. of Subjects | 13 | 9 | 3 | 1 | 15 | |
| Day 2 | Mean (SD) | 1.2 (0.6) | 1.3 (0.5) | 1.0 (0.0) | 1.0 (-) | 1.2 (0.5) |
| No. of Events | 41 | 12 | 3 | 1 | 26 | |
| No. of Subjects | 12 | 6 | - | 2 | 10 | |
| Mean (SD) | 1.5 (0.8) | 1.4 (0.7) | - | 1.0 (0.0) | 1.2 (0.4) | |
| Day 3 | No. of Events | 25 | 9 | - | 3 | 18 |
| SD, standard deviation. * IU VWF:RCo/kg. † Number of infusions where the dose per kg body weight was available. ‡ Day 1, first treatment day. |
||||||
Two prospective, open-label, non-controlled, multicenter clinical studies, one in the US and one in Europe, investigated the safety and hemostatic efficacy of Humate-P in subjects with VWD undergoing surgery.
The primary objective of this study was to demonstrate the safety and hemostatic efficacy of Humate-P in preventing excessive bleeding in adult and pediatric subjects with VWD undergoing surgery. The 35 subjects (21 female and 14 male) ranged in age from 3 to 75 years (mean 32.9); seven were age 15 or younger and two were age 65 or older. Twelve subjects had type 1 VWD, two had type 2A, three had type 2B, five had type 2M, and 13 had type 3. Twenty-eight of the surgical procedures were classified as major (e.g., orthopedic joint replacement, intracranial surgery, multiple tooth extractions, laparoscopic cholecystectomy), four as minor (e.g., placement of intravenous access device), and three subjects had oral surgery.* Seven of the 13 subjects with type 3 VWD had major surgery.
The first 15 subjects received a loading dose of Humate-P corresponding to 1.5 times the “full dose” (defined as the dose predicted to achieve a peak VWF:RCo level of 100 International Units (IU)/dL as determined by each subject’s calculated IVR and baseline VWF:RCo level); the loading dose did not vary with the type of surgery performed (i.e., major, minor, or oral). The remaining 20 subjects were dosed based on individual pharmacokinetic assessments and target peak VWF:RCo levels of 80 to 100 International Units (IU)/dL for major surgery and 50 to 60 International Units (IU)/dL for minor or oral surgery, respectively. All 35 subjects received initial maintenance doses corresponding to 0.5 times the full dose at intervals of 6, 8, or 12 hours after surgery as determined by their individual half-lives for VWF:RCo; subsequent maintenance doses were adjusted based on regular measurements of trough VWF:RCo and FVIII:C levels. The median duration of treatment was 1 day (range: 1 to 2 days) for oral surgery, 5 days (range: 3 to 7 days) for minor surgery, and 5.5 days (range: 2 to 26 days) for major surgery.
The primary objective of this study was to assess the ability of Humate-P to effectively correct the coagulation defect in subjects with VWD undergoing elective surgery, as demonstrated by an increase in VWF:RCo and FVIII, a shortening of the prolonged bleeding time, and the prevention and/or cessation of excessive bleeding. This study did not have a pre-stated hypothesis to evaluate hemostatic efficacy. The 27 subjects (18 females and nine males) ranged in age from 5 to 81 years (median age: 46 years); one was age 5, and five were older than 65. Ten subjects had type 1 VWD, nine had type 2A, one had type 2M, and seven had type 3. Sixteen of the surgical procedures were classified as major (orthopedic joint replacement, hysterectomy, multiple tooth extractions, laparoscopic adnexectomy, laparoscopic cholecystectomy, and basal cell carcinoma excision). Six of the seven subjects with type 3 VWD had major surgery.
Dosing was individualized based on a pharmacokinetic assessment performed before surgery. The median duration of treatment was 3.5 days (range: 1 to 17 days) for minor surgery and 9 days (range: 1 to 17 days) for major surgery.
In both studies, assessments of the hemostatic efficacy of Humate-P in preventing excessive bleeding were performed at the end of surgery, 24 hours after the last infusion of Humate-P, and at the end of the study (14 days following surgery).
Table 10 summarizes the end-of-surgery hemostatic efficacy assessments in subjects participating in either the US or European study.
Table 10: Investigator’s End-of-Surgery Hemostatic
Efficacy Assessments for the US and European Surgical Studies
| Number of Subjects | End-of-Surgery Hemostatic Efficacy Assessments | ||
| Effective (Excellent / Good)* | 95% Confidence Interval (CI) for Effective Proportion† | ||
| US study | 35 | 32 (91.4%) | 78.5-97.6% |
| European study | 26‡ | 25 (96%) | 82-99.8% |
| * Excellent: Hemostasis clinically not significantly
different from normal. Good: Mildly abnormal hemostasis in terms of quantity
and/or quality (e.g., slight oozing). † 95% CIs according to Blyth-Still-Casella. ‡ One subject with missing information. |
|||
Table 11 summarizes the overall hemostatic efficacy assessments in subjects participating in either the US or European study. Humate-P was effective in preventing excessive bleeding during and after surgery.
Table 11. Investigator’s Overall Hemostatic Efficacy
Assessments for the US and European Surgical Studies
| Number of Subjects | Overall Hemostatic Assessments | ||
| Effective (Excellent / Good)* | 95% CI for Effective Proportion† | ||
| US stud‡ | 35 | 35 (100%) | 91.3-100% |
| European study§ | 27 | 26 (96.3%) | 82.5-99.8% |
| * Excellent: Hemostasis clinically not significantly
different from normal. Good: Mildly abnormal hemostasis in terms of quantity
and/or quality (e.g., slight oozing). † 95% CIs according to Blyth-Still-Casella. ‡ Overall hemostatic efficacy was assessed 24 hours after the last Humate-P infusion or 14 days after surgery, whichever came earlier. § Overall hemostatic efficacy was not prospectively defined for the European study; the efficacy result displayed is the least efficacious ranking assigned by an investigator between surgery and Day 14. |
|||
In the US study, all efficacy assessments were reviewed by an independent Data Safety Monitoring Board (DSMB). The DSMB agreed with the investigators’ assessments
of the overall hemostatic efficacy for all but two subjects (neither of whom had type 3 VWD). Based on this, the DSMB judged hemostatic efficacy as “effective” in 33 (94.3%) (95% CI: 81.1% to 99.0%) of the 35 subjects.
In the US study, the median actual estimated blood loss did not exceed the median expected blood loss, regardless of the type of surgery. Table 12 shows the median expected and actual estimated blood loss during surgery in the US study.
Table 12: Expected and Actual Estimated Blood Loss
During Surgery in the US Study
| Estimated Blood Loss | Oral Surgery (n=3) |
Minor Surgery (n=4) |
Major Surgery (n=28) |
Total (n=35) |
| Expected - Median (range) mL | 10 (5-50) | 8 (0-15) | 50 (0-300)* | 20 (0-300)* |
| Actual - Median (range) mL | 3 (0-15) | 3 (0-10) | 26 (0-300)† | 18 (0-300)† |
| * One subject with missing information † Five subjects with missing information |
||||
In the US study, four subjects received transfusions, three due to adverse events and one due to pre-existing anemia. In the European study, one subject received transfusions to treat pre-existing anemia.
Clinical evidence of the absence of virus transmission in Humate-P was obtained in additional studies.
In one study, none of the evaluable subjects (31 of 67) who received Humate-P developed HBV infection or showed clinical signs of non-A, non-B (NANB) hepatitis infection.
In another study, 32 lots of Humate-P were administered to 26 subjects with hemophilia or VWD who had not previously received any blood products. No subject developed any signs of an infectious disease, and the 10 subjects not previously vaccinated remained seronegative for markers of infection with HBV, HAV, cytomegalovirus (CMV), Epstein-Barr virus, and HIV.
In a retrospective study, 155 subjects evaluated remained negative for the presence of HIV-1 antibodies for time periods ranging from 4 months to 9 years from the initial administration of Humate-P. All 67 of the subjects tested for HIV-2 antibodies remained seronegative.
REFERENCES
* Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients.
5. Hoyer LW. The factor VIII complex: structure and function. Blood. 1981;58:1-13.
6. Meyer D, Girma J-P. von Willebrand factor: structure and function. Thromb Haemostas. 1993;70:99-104.
7. Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virusinactivated factor VIII concentrates. Eur J Haematol. 1988;40:205-214.
8. Berntorp E. Plasma product treatment in various types of von Willebrand's disease. Haemostasis. 1994;24:289-297.
Inform patients that Humate-P is made from human plasma (part of the blood) and may contain infectious agents that can cause disease (e.g., viruses, the variant Creutzfeldt- Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt- Jakob (CJD) agent). Explain that the risk that Humate-P may transmit an infectious agent has been reduced by screening plasma donors, by testing the donated plasma for certain virus infections, and by inactivating and/ or removing certain viruses during manufacturing [see WARNINGS AND PRECAUTIONS].
Inform patients that some viruses, such as B19V and HAV, may be particularly difficult to remove or inactivate. Advise patients, especially pregnant women and immune-compromised individuals, to report low-grade fever, rash, joint pain, anorexia, nausea, vomiting, fatigue, and jaundice [see WARNINGS AND PRECAUTIONS].
